Skip to content

medcelerator · clinician one-pager

Once-Weekly Basal Insulin Shot for Adults with Type 2 Diabetes

Onswik (insulin efsitora alfa-gobe) — once-weekly basal insulin for adults with type 2 diabetes

FDA Approved · United States, European Union · September 25, 2026

Condition: Type 2 Diabetes

Who this is for

This is for adults with type 2 diabetes — and caregivers helping them — who may be candidates for a once-weekly basal insulin instead of a daily basal shot. It explains FDA approval of Onswik (insulin efsitora alfa-gobe) on 23 September 2026 (USPI Revised 09/2026), the EU marketing authorisation of 20 August 2026, how QWINT-1–4 showed non-inferior A1C versus daily glargine or degludec, U-500 / U-1,000 KwikPen dosing honesty, and why this is a different carton from Awiqli (insulin icodec) — without treating Onswik as type 1 insulin, mixing pens, or assuming every country has funded supply. Authorized is not funded.

Next clinical step

This is FDA authorised, not Health Canada authorised. Ask the clinician about US care, a trial, or a Special Access Programme path in United States, European Union.

Access doors

Not medical advice. Authorized is not funded. Full piece: https://medcelerator.com/articles/onswik-insulin-efsitora